Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs ThredUp Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.26 (market cap $8.04B), while ThredUp Inc trades at $6.62 (market cap $817.47M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 9.8× ThredUp Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| BIO | TDUP | |
|---|---|---|
Market Cap | $8.04B | $817.47M |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $12.08 |
52-Week Low | $241.71 | $3.11 |
Enterprise Value | $7.85B | $820.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
TDUP trades at $6.18, down 6.36% over 24 hours, with a mixed technical picture showing bullish moving averages but bearish oscillators. The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, though net losses persist. Recent news highlights the launch of a peer-to-peer marketplace and AI-driven shopping features, signaling innovation efforts. Analyst sentiment remains positive with a consensus price target of $6.90 and 57% buy ratings.
The outlook hinges on TDUP's ability to leverage AI for cost reduction and growth in its resale platform, but risks include sustained profitability challenges and competitive pressures. With cash flow improving and debt levels manageable, the stock offers speculative upside if execution aligns with bullish analyst expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
